MedTrace Logo

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-07-31

No results posted yet for this study

Summary

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Conditions

  • Corneal Neovascularization

Interventions

COMBINATION_PRODUCT

30 minute photoactivation of riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes

COMBINATION_PRODUCT

10 minute photoactivation of riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes

Sponsors & Collaborators

  • Cornea Research Foundation of America

    collaborator OTHER

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, Jr., MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2026-07-15
Completion
2026-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04787471 on ClinicalTrials.gov